@ThinklabCancer

Retweeting top stories from the thought leaders of @thinklab's Cancer Research community: https://xitter.cf/t.co/aWMhs8wdHD

Joined August 2017
  • Tweets499
  • Following14
  • Followers54
Replying to @EJonasch
@EJonasch @MDAndersonNews & team in @TheLancetOncol —> Pazopanib has promising activity in von Hippel-Lindau disease @VHLAlliance: may be useful in those with growing lesions or to reduce the size of unresectable lesions. bit.ly/2MHyFPn @montypal @OncHahn @PauloBergerot – at Holladay, UT
1
6
1
12
Thinklab Cancer retweeted
Vincent Rajkumar
@VincentRK18 Sep 2018
Criteria for High Risk Smoldering Myeloma. Also see Revised Mayo 20-2-20 risk stratification (20%BMPC, 2g/dL M protein, 20 FLC ratio) #myelomaVR @MayoMyeloma @mtmdphd @MyelomaTeacher onlinelibrary.wiley.com/doi/…
2
40
3
49
Very nice analysis by the Wash U group showing persistence of disease-associated mutations at day +30 post allogeneic transplantation are predictive of PFS and relapse risk in MDS patients. #bmtsm #leusm nejm.org/doi/full/10.1056/NE…

Mutation Clearance after Transplantation for Myelodysplastic Syndrome | NEJM

Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for patients with myelodysplastic syndrome (MDS). The molecular predictors of disease progression after transplanta...

nejm.org
4
1
10
Thinklab Cancer retweeted
Toni Choueiri, MD
@DrChoueiri11 Sep 2018
Big news just in...Combo of PD-L1 inh. Avelumab + TKI axitinib is the 1st + IO/TKI PIII that met PFS 1*endpoint irrespective of PD-L1! ⁦@pfizer⁩ ⁦@DanaFarber⁩ ⁦@kcCURE⁩ ⁦@IKCCorg⁩ ⁦@KidneyCancer⁩ Great day for RCC patients! markets.businessinsider.com/…
4
62
10
140
Thinklab Cancer retweeted
Eric Topol
@EricTopol11 Sep 2018
Our current approach to #cancer treatment, despite some modest improvements, is still far from precise. @LizSzabo @KHNews gets real & reminds us of the long road ahead. nytimes.com/2018/09/11/opini… @nytopinion
3
42
6
70
Thinklab Cancer retweeted
STAT
@statnews5 Sep 2018
He is analytical and reflective, a lofty dreamer. She will joke and kvetch and needle. Together they have made a life together — and together they are confronting the unthinkable. buff.ly/2LXITec
8
7
30
Provocative article @TheLancetOncol RCTs are being done with the aim of gaining regulatory authorisation, while testing trivial clinical questions. Hence the importance of academics trials thelancet.com/journals/lanon…
22
1
21
Thinklab Cancer retweeted
d.planchard@dplanchard3 Sep 2018
MET exon 14-altered lung cancers express PD-L1, but TMB is low and few responses to PD-1 blockade. ⁦@Annals_Oncology⁩ academic.oup.com/annonc/adva…
1
18
2
37
Thinklab Cancer retweeted
Brian Kavanagh@BK_radiation31 Aug 2018
She’s worn both a hospital gown and a white coat. Now she wants to change how doctors perceive... statnews.com/2018/08/31/shek… via @statnews
4
1
10
Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials ja.ma/2LIfHYr

Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials

This analysis investigates the prevalence of financial relationships between oncologist authors of clinical drug trials and the pharmaceutical industry and how often such financial interests are...

jamanetwork.com
2
5
1
9
Thinklab Cancer retweeted
Eric Topol
@EricTopol29 Aug 2018
It's high time to transcend @usnews ratings and move to indvidualized ratings of hospitals nejm.org/doi/full/10.1056/NE… rand.org/health/projects/per… @NEJM by @MWFriedberg @RANDCorporation @minhealthnz @BrighamWomens
4
20
3
53
UK rejects Gilead's CAR-T cancer cell therapy as too expensive reut.rs/2P9zeDo
1
23
13
12
Thinklab Cancer retweeted
PCF Science@PCF_Science28 Aug 2018
Announcing the 2018 Class of PCF Young Investigators! We are so proud to fund these amazing early career scientists who have dedicated their careers to ending #ProstateCancer! #PCFfunded @PCFnews @manyvscancer pcf.org/news/the-prostate-ca…
2
14
11
40
Thinklab Cancer retweeted
Nature Genetics@NatureGenet27 Aug 2018
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (Miao et al.) go.nature.com/2oditLV
3
84
7
140
Thinklab Cancer retweeted
Eric Topol
@EricTopol26 Aug 2018
The #1 supplement—fish oil—taken by tens of millions Americans for billions of dollars/yr. And the latest trial to debunk any value in them. nejm.org/doi/full/10.1056/NE… @NEJM #ESCCongress
53
408
72
636
McCain said in a statement that he has surpassed expectations for his survival since his diagnosis. "But the progress of disease and the inexorable advance of age render their verdict," and the senator has decided to end medical treatment. wapo.st/2wn2Ipp
122
277
105
616
Thinklab Cancer retweeted
Dr Sunil Verma@cancermd23 Aug 2018
SOLAR-1 Trial (PI3-k Inh. Alpelisib in Metastatic Breast Cancer) met primary endpont of PFS. Key things to look when data is reported(likely #ESMO18 ): 1. Toxicity profile 2. Magnitude of diff. in PFS 3. Efficacy in CDK4/6 tx patients 4. PI3k test profile novartis.com/news/media-rele…

SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets...

novartis.com
1
22
3
50
Thinklab Cancer retweeted
Ahmad Tarhini@ATarhiniMDPhD23 Aug 2018
Proud to be part of this groundbreaking work & awesome collaborative group / @NEJM / #Melanoma brain metastasis can be definitively teated w #immunotherapy marking a new era in #Immunooncology #Cancerresearch nejm.org/doi/full/10.1056/NE… @CleClinicMD #CleClinicCancer @caseccc

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain | NEJM

Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melano...

nejm.org
16
1
28
Our work on Steroids and PD-(L)1 Blockade. This is not randomized data, and pts that need steroids have probably a poorer prognosis (because of symptomatic brain or bone mets, recent radiotherapy...). Pts should receive IO when indicated, even w steroids. ascopubs.org/doi/full/10.120…

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1...

PurposeTreatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive effect of corticosteroids...

ascopubs.org
19
4
42
Thinklab Cancer retweeted
FabriceAndre@FAndreMD21 Aug 2018
ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decrease the misinterpretation of genomic reports together with overtreatment. Now we need to work on implementation. tks to all authors ! academic.oup.com/annonc/adva…
2
46
5
78
Load more